The U.S. IPO market continued to lose momentum in the week ended October 9, 2026, as newly listed biotechnology companies delivered mixed results and investors remained selective about new offerings. The Renaissance IPO Index fell 0.5%, underperforming the S&P 500’s 1.2% gain. Meanwhile, software and technology-related stocks led the market’s strongest performers, and seven sizable companies filed IPO paperwork, including Singapore-based DayOne Data Centers and African fintech company OPay.

Biotech IPOs Face a More Selective Market

Four biotechnology IPOs entered the market during the week, with two pricing and beginning trading while two additional offerings were scheduled for the following week. TRex Bio (Nasdaq: TRXB), which is developing treatments for autoimmune and inflammatory diseases, raised $117 million by pricing its shares at $14, the bottom of its proposed range. The stock opened below its offer price and finished the week flat, marking the first biotech IPO to price below the midpoint since February 2025, according to the source.

Retension Pharmaceuticals (Nasdaq: RTSN), which is developing a treatment for uncontrolled and resistant hypertension, raised $45 million in its IPO but ended the week down 12%. The weaker performance of these recent listings suggests investors are becoming more selective after a strong track record among biotechnology IPOs in 2026. Earlier enthusiasm attracted participation in less compelling deals and supported stretched valuations, but recent losses could shift demand toward companies with stronger development prospects and more attractive pricing.

Iambic Therapeutics and City Therapeutics Prepare to List

Two larger biotechnology offerings were lined up for the week ahead. Iambic Therapeutics (Nasdaq: IAM) is developing medicines using a proprietary artificial intelligence platform, while City Therapeutics (Nasdaq: CTY) is seeking to capitalize on investor interest in RNA interference therapies. Their offerings will test whether investors remain willing to fund clinical-stage biotechnology businesses after the weaker performance of recent listings. Both companies operate in areas attracting interest in drug discovery and advanced therapeutic development, but investor reception will depend on the proposed terms and broader market appetite.

Anthropic IPO Keeps Investors Cautious

The broader IPO market continued to tread water, with the Renaissance IPO Index trading below its 50-day moving average. A significant segment of Wall Street is reportedly keeping capital on the sidelines while waiting for Anthropic’s potential IPO, while long-term investors are looking for more attractive entry points among listed companies.

The market pause reflects a reassessment of valuations and deal quality rather than a complete disappearance of IPO demand. The source identifies a resolution to the Iran war as the biggest potential catalyst for improved sentiment, followed by better inflation data and strong corporate earnings. Even without an immediate catalyst, the passage of time could bring the market closer to a more active issuance calendar.

Seven Companies File IPO Paperwork

Despite subdued trading, IPO candidates continued to advance their plans. Seven sizable companies submitted IPO paperwork during the week, led by DayOne Data Centers, a Singapore-based data center developer, and OPay, an African fintech company. Their filings indicate that potential issuers are continuing to prepare for public-market access even as investors become more demanding about pricing, growth prospects and business quality.

DayOne operates in the data center infrastructure market, which supports cloud computing and digital services, while OPay represents fintech exposure in African markets. Their eventual offerings could provide further evidence of investor appetite for large international issuers.

Weekly IPO Winners and Losers

The Renaissance IPO Index returned negative 0.5% through October 9, underperforming the S&P 500’s 1.2% advance. Bending Spoons led the weekly winners with an 18.7% gain, followed by Netskope at 16.9%, Klarna Group at 12.4%, Chime Financial at 10.4% and Navan at 10.3%.

EquipmentShare.com was the weakest performer, falling 18.5%. SK hynix declined 13.4%, Quantinuum lost 10.4%, CoreWeave fell 8.4% and Tempus AI dropped 7.4%. The spread between the strongest and weakest performers highlights the market’s uneven appetite for recently listed companies, particularly across technology and AI-sensitive businesses.

Sector Performance Remains Mixed

Consumer discretionary stocks led the listed IPO sectors with a 3.2% gain, followed by financials at 3.0% and technology at 2.7%. Energy advanced 1.6%, while healthcare was nearly unchanged, slipping 0.1%. Real estate declined 0.9%, consumer staples fell 1.3% and industrials lost 2.7%. Utilities recorded the largest sector decline, dropping 4.8%.

The divergence indicates that investors continued to reward selected companies and industries while remaining cautious toward other sectors. Positive returns in technology and financials did not prevent the broader IPO index from finishing the week lower.

Market Context and Opportunities

The week’s results point to a more selective IPO environment. Gains among software and fintech names show that demand remains available for companies investors consider attractive, while weaker biotechnology listings suggest that sector enthusiasm alone may no longer be enough to support new offerings.

The continued flow of IPO filings indicates that potential issuers are preparing for opportunities despite the slowdown. If market conditions improve, large candidates such as DayOne Data Centers and OPay could help revive issuance activity. However, successful launches will likely depend on realistic valuations, compelling business prospects and a more supportive equity-market environment.

Risks and Challenges

The IPO market remains vulnerable to geopolitical uncertainty, inflation trends, broader equity-market performance and concerns about valuation. A sustained period of weak post-IPO returns could encourage companies to delay offerings and make investors more selective about new deals. Biotechnology issuers face additional uncertainty because clinical-stage businesses depend on research results and development milestones. The performance of TRex Bio and Retension Pharmaceuticals illustrates how new listings can struggle even when their sector has previously attracted strong investor interest.

Closing Paragraph

The U.S. IPO market ended the week of October 9 with the Renaissance IPO Index down 0.5%, while the S&P 500 gained 1.2%. Weak post-listing performance among recent biotechnology offerings, continued caution ahead of Anthropic’s potential IPO and broader market uncertainty are weighing on sentiment. Nevertheless, seven sizable filings, including DayOne Data Centers and OPay, show that the IPO pipeline remains active as investors wait for stronger conditions and more compelling opportunities.